BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Celeris Therapeutics

Celeris Therapeutics logo

Website
https://celeristx.com/
Founded
2020
Patents
1
Publications
5

Technologies

AI Companies (Drug Discovery) Protein Degraders Startups

Celeris Therapeutics is going to solve the R&D shortcomings as the pioneer in AI-driven PIC (proximity-inducing compounds) design using an innovative closed-loop engine (Celeris One™ platform) to develop new chemical entities (NCEs) that degrade proteins by establishing proximity to endogenous cellular mechanisms. The solutions include machine learning-driven prediction of interactions, generative design, optimization of molecular properties, and automation of laboratory devices.


Posts Mentioning This Company

12 Notable AI-powered Biotech Companies Founded in 2021

June 23, 2023  
Ever since the early 2000s, Artificial Intelligence (AI) has become a useful tool in various fields, from game design and speech recognition to powering driving cars and military applications. No wonder that big pharma companies are striving to keep up with technological progress and implementing AI in their internal R&D …

7 Companies Using AI to Design Protein Degraders

Nov. 28, 2022  
Our cells function in the continuous mode of producing and degrading proteins, keeping the balance between these two processes to maintain a healthy cellular function. However, sometimes the produced proteins might be defective, accumulating and causing pathological effects. This is one of the examples when hijacking the naturally occurring process …

Protein Degraders Take Industry By Storm

Oct. 18, 2022  
Proteins are essential components of living matter — they function as building blocks for cells and tissues, as well as participate in signaling and practically all biochemical activities.  However, each protein operates correctly only for a limited time and is eliminated by molecular machinery after it has reached its “functional …

Meet the Company Using Artificial Intelligence for Designing Targeted Protein Degraders

May 11, 2022  
Proteins are essential components of living matter – they function as building blocks for cells and tissues, as well as participate in signaling and practically all biochemical activities. However, each protein operates correctly only for a limited amount of time and is eliminated by molecular machinery after it has reached …

Pharmaceutical AI in 2021: Key Developments So Far

Aug. 9, 2021  
Table of Contents:   Introduction Artificial intelligence (AI) in drug discovery yields breakthroughs The abundance of venture capital, major funding rounds IPOs of AI Pharma Companies in 2021 New AI-driven biotech startups founded in 2020 Notable AI-focused collaborations involving “big pharma” players AI adoption by the contract research organizations (CROs)  …
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

Case Studies


  • Application of AI-driven Xanthos Platform for Designing Protein Degraders

R&D Platform

Celeris One – Cutting-edge deep learning combined with robotization on proximity-inducing compounds (PICs).
To create the perfect drug, we do not only rely on existing data. Our platform uses innovative methods such as Graph Representation Learning, Active Learning & Bayesian Optimization, Generative Models & Data Augmentation to expand the chemical space and leverage sparse and heterogeneous data to identify potent small molecule degraders and more proximity-inducing compounds.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.